Clinical Journal of Gastroenterology

, Volume 11, Issue 2, pp 150–155 | Cite as

A case of severe stenosis of hepatic veins and inferior vena cava with stomal variceal bleeding induced by oxaliplatin-based chemotherapy

  • Hayato Yamaguchi
  • Yoshihiro Furuichi
  • Yoshitaka Kasai
  • Hirohito Takeuchi
  • Yuu Yoshimasu
  • Katsutoshi Sugimoto
  • Ikuo Nakamura
  • Takao Itoi
Case Report


A 27-year-old woman with colon cancer and liver metastasis was referred to our hospital. Colectomy and colostomy were performed to improve her ileus. Following 13 sessions of oxaliplatin-based chemotherapy (OC) with mFOLFOX6 + bevacizumab, thrombocytopenia and frequent peristomal bleeding occurred. Computed tomography showed severe ascites, splenomegaly, significant collateral veins around the stoma, and severe stenosis of the hepatic veins (HV) and inferior vena cava (IVC). Ultrasound elastography showed high liver (and spleen) stiffness values. Repeated OC appeared to cause IVC stenosis as a result of worsening sinusoidal obstruction syndrome (SOS), and peristomal variceal bleeding. After ultrasound-guided percutaneous embolization, bleeding did not recur. Unfortunately, the patient died of liver dysfunction caused by severe SOS. The incidence of OC-induced SOS is reported to be about 50%; however, there is apparently no report of OC-induced HV and IVC stenosis, and in most cases, portal hypertension is improved after OC cessation. This is the first report of OC-induced severe HV and IVC stenosis resulting in refractory peristomal variceal bleeding and eventual death.


Oxaliplatin Hepatic vein Inferior vena cava Sinusoidal obstruction syndrome Colon cancer 



Oxaliplatin-based chemotherapy


Hepatic veins


Inferior vena cava


Sinusoidal obstruction syndrome


Computed tomography


Graft versus host disease




Matrix metalloproteinase


Vascular endothelial growth factor


Budd–Chiari syndrome


Right hepatic vein



We thank Dr. Edward Barroga (, Associate Professor and Senior Medical Editor from the Department of International Medical Communications of Tokyo Medical University for reviewing and editing the manuscript. This case report was partly supported by a Health Labour Sciences Research Grant from Research on Measures for Intractable Diseases and the Intractable Hepato-Biliary Diseases Study Group in Japan.

Authors’ contribution

HY (drafting of the manuscript, literature search, data collection, figures, performing chemotherapy and endoscopy); YF (drafting the manuscript, figures, table, data interpretation, concept design, performing IVR); YK (CT images and data collection); HT and YY (performing IVR, exploration of medical record); KS and IN (literature search, performing ultrasonography); TI (concept design)

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Financial support

This study was partly supported by a Health and Labour Sciences Research Grant from the Japanese Ministry of Health, Labour and Welfare for Research on Intractable Diseases and Portal Hemodynamic Abnormalities.

Human rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.


  1. 1.
    de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–47.CrossRefPubMedGoogle Scholar
  2. 2.
    Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010;56:430–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Soubrane O, Brouquet A, Zalinski S, et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010;251:454–60.CrossRefPubMedGoogle Scholar
  4. 4.
    Narita M, Oussoultzoglou E, Chenard MP, et al. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization. Ann Surg Oncol. 2012;19:2230–7.CrossRefPubMedGoogle Scholar
  5. 5.
    van den Broek MA, Vreuls CP, Winstanley A, et al. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol. 2013;20:1462–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Vreuls CP, Driessen A, Olde Damink SW, et al. Sinusoidal obstruction syndrome (SOS): a light and electron microscopy study in human liver. Micron. 2016;84:17–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou H, Wang YX, Lou HY, et al. Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features. Korean J Radiol. 2014;15:218–25.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Erturk SM, Mortelé KJ, Binkert CA, et al. CT features of hepatic venoocclusive disease and hepatic graft-versus-host disease in patients after hematopoietic stem cell transplantation. Am J Roentgenol. 2006;186:1497–501.CrossRefGoogle Scholar
  9. 9.
    Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Deleve LD, Wang X, Tsai J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;125:882–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Hubert C, Sempoux C, Humblet Y, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford). 2013;15:858–64.CrossRefGoogle Scholar
  12. 12.
    Bloor K, Orr W. A case of hemorrhage from varices in the small intestine due to portal hypertension. Br J Surg. 1961;48:423–4.CrossRefGoogle Scholar
  13. 13.
    Mukund A, Pargewar SS, Desai SN, et al. Changes in liver congestion in patients with Budd–Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–687.CrossRefPubMedGoogle Scholar
  14. 14.
    Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology. 2010;257:872–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Taniguchi T, Sakata Y, Ohtani T, et al. Usefulness of transient elastography for noninvasive and reliable estimation of right-sided filling pressure in heart failure. Am J Cardiol. 2014;113:552.CrossRefPubMedGoogle Scholar
  16. 16.
    Jalal Z, Iriart X, De Lédinghen V, et al. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases. Heart. 2015;101:1499–504.CrossRefPubMedGoogle Scholar
  17. 17.
    Miura K, Nakano H, Sakurai J, et al. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011;16:257–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Imai K, Emi Y, Iyama KI, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014;40:559–66.CrossRefPubMedGoogle Scholar
  19. 19.
    Furuichi Y, Moriyasu F, Taira J, et al. Noninvasive diagnostic method for idiopathic portal hypertension based on measurements of liver and spleen stiffness by ARFI elastography. J Gastroenterol. 2013;48:1061–8.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2018

Authors and Affiliations

  1. 1.Department of Gastroenterology and HepatologyTokyo Medical UniversityTokyoJapan

Personalised recommendations